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Abstract  
Currently available antiepileptic drugs (AEDs) fail to control seizures in 30% of patients. 
Genomics-based drug repurposing (GBR) offers the potential of savings in the time and cost of 
developing new AEDs. In the current study, we used published data and software to identify the 
transcriptomic signature of chornic temporal lobe epilepsy and the drugs that reverse it. After 
filtering out compounds based on exclusion criteria, such as toxicity, 36 drugs were retained. 11 
of the 36 drugs identified (>30%) have published evidence of antiepileptic efficacy (for example, 
curcumin) or antiepileptogenic affect (for example, atorvastatin) in recognised rodent models or 
patients. By objectively annotating all 20,000 compounds in the LINCS database as either 
having published evidence of antiepileptic efficacy or lacking such evidence, we demonstrated 
that our set of repurposable drugs is ~6-fold more enriched with drugs having published evidence 
of antiepileptic efficacy in animal models than expected by chance (p-value <0.006). Further, we 
showed that another of our GBR-identified drugs, the commonly-used well-tolerated 
antihyperglycemic sitagliptin, produces a dose-dependent reduction in seizures in a mouse model 
of pharmacoresistant epilepsy. In conclusion, GBR successfully identifies compounds with 
antiepileptic efficacy in animal models and, hence, it is an appealing methodology for the 
discovery of potential AEDs. 
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Introduction 
Epilepsy is amongst the most common neurological disorders: 65 million people have epilepsy 
worldwide (1). Currently available AEDs (AEDs) have been identified using traditional drug-
discovery approaches (2): serendipity, phenotypic screening, hypothesis-driven target-orientated 
design, and structural modification of existing molecules. These compounds act primarily upon a 
small number of targets involved mainly in modulating neuronal excitability (2). Currently 
available AEDs have a number of significant shortcomings. They fail to control seizures in 30% 
of patients (3), and possess no antiepileptogenic or disease-modifying activity (4, 5). In addition, 
they do not exhibit any meaningful efficacy against significant epilepsy comorbidities (6), such 
as cognitive impairment and psychiatric conditions. Over 100 years of utilising traditional drug 
discovery approaches for the development of an increasingly long list of approved AEDs, now 
approaching 30, has failed to overcome these challenges. A need exists, therefore, for newer 
more effective AED-discovery approaches. 
 
In recent years, there has been an increasing interest in exploiting genomics-based drug 
repurposing (GBR) to aid and accelerate the drug discovery process. GBR is based on the 
following precepts (7). Every biological state and, hence, every disease state can be described by 
a gene expression signature. Treatments that restore gene expression patterns to their norm are 
associated with the successful restoration of the disease phenotype (8). The methodology can be 
summarised as follows (9). The first step is to generate a signature of differential gene expression 
for the disease through a genome-wide gene expression analysis comparing normal tissue with 
the disease tissue of interest. Then, using the gene expression signature of disease, databases of 
drug-induced gene expression signatures, such as Connectivity Map (cMap) and Library of 
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Integrated Network-based Cellular Signatures (LINCS) are queried. These databases contain 
drug-induced signatures of differential gene expression for thousands of compounds. Each 
signature is generated through genome-wide gene expression analysis comparing cells before 
and after drug exposure. If disease- and drug-induced signatures are sufficiently negatively 
correlated (i.e. the genes upregulated in the disease-induced signature are downregulated in the 
drug-induced signature and vice versa) then the effect of the drug on transcription is opposite to 
the effect of the disease. Hence, the drug might revert the disease signature of differential gene 
expression and the disease phenotype itself. GBR has successively produced a number of 
therapeutic leads for different diseases (8-11). 
 
GBR holds much promise for drug discovery in epilepsy. It is known that hundreds of genes 
influence susceptibility to epilepsy (12) and are altered in the epileptic focus (13, 14). By 
targeting these dysregulated genes, and restoring global gene expression patterns to their healthy 
norm, repurposed drugs could ameliorate the diverse pathological changes that create and 
promote the hyperexcitable neuronal network which generates seizures. Hence, this approach 
offers the potential of efficacy against epilepsy, epileptogenesis, and the comorbidities that share 
genes, biological pathways and pathophysiological mechanisms with epilepsy. 
 
Results  
The transcriptomic signature of epilepsy and the drugs that reverse it 
The transcriptomic signature of disease was extracted from a published RNA sequencing 
analysis of a mouse model of chronic temporal lobe epilepsy (TLE) (15). The genes constituting 
the transcriptomic signature of TLE used in the current study are listed in Table S1. 
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Drugs that reverse the epileptic transcriptomic signature were identified using the Library of 
Integrated Network-based Cellular Signatures (LINCS) data and software. 123 compounds 
(Table S2) met the inclusion criterion (LINCS mean connectivity score threshold of -85). After 
filtering out compounds (Table S2) based on the exclusion criteria of toxicity, parenteral route of 
administration, lack of animal or human dosage data, or BBB-impermeability, 36 compounds 
remained (Table S3). We found no explicit published evidence of BBB-impermeability for any 
of the drugs; most have never undergone an in vitro or in vivo assessment of BBB-permeability. 
The known primary mode of action of each of the 36 compounds is listed in Table S3.  
 
Dissimilar drugs modulate the same biological pathways 
We used the Drug-Set Enrichment Analysis (DSEA) tool to demonstrate that that the identified 
compounds, although pharmacologically diverse, are alike in modulating biological pathways. 
DSEA showed that the unselected sample of five GBR-identified drugs with varying modes of 
action shared 134 (out of 669) Reactome pathways at a significance threshold of p<0.05 (Table 
S4). The median number of significant pathways shared by 1000 randomly-selected five-
compound drug-sets was 31, the mean was 33.2, and the range was 10-98 (Table S5 and Figure 
S1). Hence, none of the 1000 random drug-sets shared 134 pathways, demonstrating that the 
number of pathways shared by GBR-identified drugs is statistically significant (permutation-
based p-value <0.001). 
 
Repurposable drugs are better than conventional AEDs at reversing the pathway dysregulation 
underlying epilepsy 
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The Reactome pathways most significantly dysregulated in TLE were identified by performing 
Gene-Set Enrichment Analysis (http://www.broadinstitute.org/gsea/) separately on the up- and 
down-regulated genes constituting the transcriptomic signature of TLE identified above. The 
hundred most up-regulated and the hundred most down-regulated pathways were noted; the 
degree of enrichment was statistically significant (FDR<0.05) for all of these 200 pathways. 29 
pathways were both up- and down-regulated; these pathways were excluded. It should be noted 
that in the Reactome database, pathways are assembled into a hierarchy of biological processes. 
The top hierarchy of biological processes represent very broad categories, such as 
‘Developmental Biology’ and ‘Neuronal System’, within which subcategories can be differently 
dysregulated; this was the case with the 29 pathways both up- and down-regulated in the current 
analysis. Of the 142 (out of 200) pathways remaining, one was not present in the DSEA database 
(as the database excludes the very smallest and largest pathways) leaving 141 pathways to be 
considered in the present analysis. 
 
We hypothesized that repurposable drugs are better than conventional AEDs at rectifying the 
dysregulated pathways identified above. In turn, each repurposable drug present in the in the 
DSEA database was compared with the set of conventional AEDs present in the DSEA database. 
Table S6 and Figure 1 show the percentage of dysregulated pathways corrected most effectively 
by each drug. In each comparison, the repurposable drug was the best performing compound for 
the highest proportion of pathways. The fraction of dysregulated pathways for which the 
repurposable drug surpassed conventional AEDs was statistically significant (binomial test 
FDR<0.05) for all comparisons.  
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The set of identified compounds is enriched with AEDs 
At the time of conducting this analysis, there were 19,767 unique compounds within the LINCS 
database. Using the strategy detailed in Methods of objective computational data retrieval and 
parsing, followed by careful manual filtering based on pre-defined exclusion criteria, 203 drugs 
(1%) were identified as possessing published evidence of antiepileptic efficacy in animal models. 
 
Of the 123 drugs included in our transcriptionally-repurposed drug-set, seven (5.7%) possessed 
published evidence of antiepileptic efficacy, which represents an approximately six-fold 
enrichment.  
 
LINCS database compounds were randomly divided into 159 sets of 123 drugs each. The median 
number of AEDs within the random drug-sets was 1, the mean was 1.2, and the range was 0-4. 
None of the random drug-sets included seven or more drugs with published evidence of 
antiepileptic efficacy, confirming that the enrichment of AEDs within the transcriptionally-
repurposed drug-set is statistically significant, with a permutation-based p-value of <0.006 
(=1/159 random drug-sets). This enrichment was also statistically significant according to the 
hypergeometric distribution (p<0.0003). 
 
Further details about the data used for completing this enrichment analysis, including evidence 
used for considering or discounting drugs as antiepileptic, can be found in the supplementary 
material. 
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In addition to above unsupervised computational approach for parsing information from Medline 
abstracts, which was applied to all 123 drugs identified by the LINCS computational algorithm, a 
more detailed manual literature-review was performed in order to identify additional evidence of 
antiepileptic efficacy for the 36 compounds that were selected after application of exclusion 
criteria; results for this have been summarised in Table 1. 
 
In vivo validation 
Sitagliptin, one of the drugs identified using our GBR pipeline, was chosen for in vivo validation 
as it is a commonly-used well-tolerated licensed medication. Levetiracetam, an AED which is 
well characterised and effective in this model (16, 17), was included in the drug screening to 
verify adequate execution of the screening process. Sitagliptin produced a dose-dependent 
reduction in seizure scores (Figure S2) in the 6 Hz psychomotor seizure mouse model (18) of 
pharmacoresistant epilepsy (16, 19). The mean (± standard error) seizure scores for the vehicle, 
sitagliptin 125 mg/kg, sitagliptin 250 mg/kg and sitagliptin 500 mg/kg groups were 0.93 ± 0.12, 
0.73 ± 0.18, 0.60 ± 0.14, and 0.47 ± 0.13, respectively. In keeping with published reports, the 
AED levetiracetam (16, 17) also produced a reduction in seizures scores. There was a 
statistically significant difference in seizure scores across the groups (Kruskal–Wallis p-value 
<0.05). The difference between control and treatment group seizure scores was statistically 
significant (two-sided Mann-Whitney U test FDR <0.05) for the highest dose of sitagliptin 
evaluated (500 mg/kg) and for levetiracetam. Individual seizure scores are shown in Table S9. 
 
Discussion  
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In this study, we have applied GBR to epilepsy, demonstrated that this identifies a set of 
compounds significantly enriched with drugs possessing efficacy in animal models of epilepsy, 
and presented in vivo validation of a GBR-identified drug. 
 
Our GBR strategy—identifying compounds using the LINCS algorithm and excluding those 
unsuited for oral administration—identified 36 drugs. Using DSEA, we showed that our sample 
of GBR-identified compounds exert a similar modulatory effect on 134 Reactome pathways; 
significantly greater than expected by chance (permutation-based p-value <0.001). This 
observation is useful for two reasons. Firstly, the GBR-identified compounds appear to have 
little in common with each other: they are pharmacologically diverse with different molecular 
targets. Dissimilar drugs with disparate modes of action would seem unlikely to induce the same 
antiepileptic phenotype. Our analysis shows that, in spite of their different modes of action, 
GBR-identified compounds modulate the same biological pathways, enabling them to induce the 
same therapeutic effect. Secondly, the DSEA algorithm is based on gene expression data from 
cMap, not LINCS. Hence, it is encouraging to see that an analysis using a paradigm and a 
database of drug-induced gene expression signatures different from that used to perform GBR 
corroborates the pathway-level functional similarity of our GBR-identified compounds. 
 
It is interesting to note the lack of conventional licensed AEDs amongst our GBR-identified 
compounds, which suggests that the GBR-identified compounds are more effective than some 
conventional AEDs at reversing the transcriptomic signature of TLE. In keeping with this, we 
showed, using DSEA-based analysis, that each repurposable drug in our sample is better than all 
tested conventional AEDs in rectifying the highest number of dysregulated biological pathways 
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underlying TLE. Again, it is encouraging to see that an analysis using a paradigm and a database 
of drug-induced gene expression signatures different from that used to perform GBR 
corroborates the superiority of the tested GBR-identified compounds over the tested 
conventional AEDs at correcting the TLE transcriptomic signature. Whether this mechanistic 
difference translates into a more effective, broader or disease-modifying clinical affect should be 
investigated in future functional studies. However, our bioinformatic, literature-based and in vivo 
analysis hints at this possibility, as discussed below. 
 
A number of the GBR-identified drugs have published evidence of antiepileptic or 
antiepileptogenic efficacy in animal models. Almost a third of the final 36 compounds identified 
have functional evidence of efficacy in animal models of epilepsy. We demonstrated that the 
GBR-identified drugs are significantly enriched (permutation-based p-value <0.006) with drugs 
having published evidence of antiepileptic efficacy in animal models by using a novel objective 
methodology, based upon the auto-parsing of relevant information from Medline abstracts. We 
demonstrated this enrichment within all 123 compounds identified by the LINCS algorithm, 
rather than to just the 36 compounds that remained after filtering, in order to avoid the possibility 
of perceived bias in the manual selection of the 36 compounds. 
 
As mentioned above, one motivation for seeking transcriptome-rectifying therapies is the 
anticipation of antiepileptogenic efficacy. This expectation is supported our findings: almost half 
of the compounds with published data from animal models have evidence of an antiepileptogenic 
effect (Table 1). An example is the drug lestaurtinib. Using the rat hypoxia-induced epilepsy 
model, researchers showed that administration of lestaurtinib at the time of the epileptogenic 
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insult attenuates susceptibility to seizures later in life (20). Within our list also is the first drug 
shown to be potentially antiepileptogenic in man: atorvastatin (21). After studies demonstrating 
the antiepileptogenic effects of atorvastatin in rodent models (22, 23), Guo et al. have recently 
shown that administration of statins to patients with early-onset poststroke seizures is associated 
with reduced risk of poststroke epilepsy (24). In the study by Guo and colleagues, most patients 
received atorvastatin; there were not enough data to conduct appropriate subgroup analyses 
because too few patients were given simvastatin or rosuvastatin. 
 
It is clear that epilepsy and its comorbidities, such as anxiety, depression and cognitive 
impairment, share genes, biological pathways and pathophysiological mechanisms (25-29). 
Hence, another motivation for seeking transcriptome-rectifying antiepileptic therapies is the 
anticipation of efficacy against epilepsy comorbidities. Again, this expectation is supported by 
our findings: a number of compounds with published data from animal models of epilepsy have 
evidence of an effect against comorbidities in the models. For example, atorvastatin ameliorates 
anxiety, depression and cognitive impairment (23, 30), resveratrol is effective against cognitive 
impairment and depression (31), and mepacrine ameliorates cognitive impairment (32) in rodent 
models of epilepsy. 
 
We wished to show that, in addition to the compounds with published evidence of antiepileptic 
and antiepileptogenic efficacy found to be enriched within our drug-set, other GBR-identified 
compounds yet unstudied in animal models of epilepsy also have therapeutic efficacy. We 
demonstrated that the commonly-used well-tolerated licenced antihyperglycaemic agent 
sitagliptin produces a dose-dependent reduction in seizure scores in a mouse of model of 
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pharmacoresistant epilepsy—the 6 Hz psychomotor seizures model. Seizures in this model are 
resistant to many established AEDs, for example carbamazepine, ethosuximide, lamotrigine, 
phenytoin and topiramate (33), although they are sensitive to valproic acid, levetiracetam and 
phenobarbital. Sitagliptin at twice the equivalent of the maximum dose used in the current study 
has been administered to rodents for repeated doses without adverse effect (34, 35), and 
sitagliptin equal to the maximum dose used in the current study been taken in man without 
adverse effects (36), although it is higher than the dose currently licensed for diabetes. 
Sitagliptin, on its own, does not cause hypoglycaemia (37). Prolonged courses of sitagliptin at 
different doses should be analysed in future studies to determine if they produce greater 
antiepileptic efficacy. At the same time, it is important to note that sitagliptin screening is 
presented here only as validation of our GBR approach and as a proof-of-principle. It is possible 
that there are more efficacious AEDs within our GBR-identified drug-set; the other GBR-
identified compounds should be screened in animal models of epilepsy in order to identify the 
ones that are most promising. In a recent study, intracerebroventricular injection of sitagliptin 
reduced the average electroencephalographic power spectrum induced by heperthermia; any 
affect on febrile or non-febrile seziures was not reported (38). 
 
Limitations and need for future investigations should be noted. The transcriptomic signature of 
disease used in this study was extracted from a mouse model of chronic TLE. It is possible that 
some of the transcriptomic changes in this signature are species-specific. It should be noted, 
however, that there is significant conservation of genomic networks in hippocampal tissue from 
this mouse model and people with epilepsy (39). Transcriptomic profiles from studies comparing 
human epileptic and normal postmortem hippocampi are known to include postmortem-specific 
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changes (40), which would compromise the quality of the disease signature. Another potential 
limitation is that the efficacy of a drug in rodent models does not necessarily translate to 
effectiveness in man. At the same time, it is important to note that drug screening in rodent 
models of epilepsy has been successful and crucially contributed to the development of 
numerous clinically effective AEDs (41). Finally, some of the compounds identified in this 
analysis are promising leads, rather than repurposing candidates, as they are not currently in 
routine clinical use. 
 
In future work, prolonged courses of sitagliptin and other GBR-identified compounds should be 
analysed in animal models of epilepsy in order to identify the drugs that are most promising. To 
confirm the antiepileptogenic or disease-modifying potential of the identified compounds, 
specifically designed studies that include a drug washout phase should be performed (41). With 
further supportive evidence from rodent models of epilepsy, drugs like sitagliptin and 
atorvastatin, for which there is extensive clinical experience of safe use in other conditions, 
would be promising repurposing candidates to take into clinical trials.  
 
In conclusion, this is the first study to show that GBR in epilepsy identifies a coherent set of 
compounds significantly enriched with drugs possessing efficacy in animal models of epilepsy 
and, hence, GBR is an appealing methodology for the discovery of potential AEDs. 
 
Materials and Methods 
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Experimental design 
This study has three main parts. The first part is a bioinformatic analysis to identify, using the 
LINCS software and database of drug-induced transcriptomic signatures, compounds that revert 
the transcriptomic signature of epilepsy extracted from a published RNA-sequencing study of a 
rodent model of the disease. In the second part, the success of the first part of the study is 
assessed by determining, using a permutation-based strategy, if the identified drugs are enriched 
with compounds with published evidence of efficacy in rodent models of epilepsy. In the third 
part, we perform in vivo screening of one of the identified drugs, sitagliptin, in a rodent model of 
refractory epilepsy. The sample size for the in vivo study was dictated by resource limitations, 
powering the study to 0.7 with an α error of 0.05 for the highest dose of sitagliptin screened. 
 
Identifying the transcriptomic signature of epilepsy and the drugs that reverse it 
A transcriptomic signature of chronic temporal lobe epilepsy (TLE) was generated as follows. 
Differentially expressed genes were extracted from the results of a recently published high-
throughput RNA sequencing analysis comparing hippocampal tissue from normal mice and from 
mice with pilocarpine-induced chronic epilepsy (15). The mouse genes were mapped to human 
homologues listed in the Mouse Genome Database (42). Human homologues were mapped to 
Affymetrix U133A microarray probe identifiers listed in the NetAffx database (43). Probes 
corresponding to the most differentially expressed mouse genes (FDR <0.05 & fold change 2) 
were retained. 
 
Drugs that reverse the epileptic transcriptomic signature were identified using the Library of 
Integrated Network-based Cellular Signatures (LINCS) data and software 
(http://apps.lincscloud.org/query). LINCS is successor to the highly successful Connectivity Map 
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(44), with a vastly expanded number of drugs profiled in multiple human cell lines, producing 
more than a million transcriptomic drug signatures.  
 
The LINCS software quantitates the (dis)similarity between the disease and each of the drug 
signatures. For each drug signature, the software generates a ‘connectivity score’ ranging from 
+100 to -100. A high positive connectivity score indicates that the corresponding compound’s 
transcriptomic signature is like that of the disease signature, while a high negative connectivity 
score indicates that the compound’s transcriptomic signature is opposite that of the disease. As 
each drug has been profiled in multiple human cells lines, there are multiple transcriptomic 
signatures for each drug, and multiple connectivity scores for each drug-disease combination. 
For each drug, the mean of the four highest connectivity scores across different cell lines is the 
default statistic for summarising the relationship of the drug-disease pair, in the LINCS 
algorithm. The cell lines utilised for calculating the mean connectivity score are not pre-selected 
by tissue of origin; any tissue-specific noise is thought to be drowned out by the powerful 
directionality of the induced signature (45). The mean connectivity score threshold for drug 
selection may be set at different points: a threshold score of -90 has been proposed and used in 
published literature (46). In the current study, a mean connectivity score threshold of -85 was 
chosen in order to generate a longer list of drugs for evaluation. 
 
Drugs identified using the above process were then filtered based on the following exclusion 
criteria: 
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1. Drugs included in the National Institute for Occupational Safety and Health List of 
Antineoplastic and Other Hazardous Drugs (47), or known to be toxic, according to 
published literature 
2. Drugs requiring parenteral administration 
3. Drugs with no published data to indicate effective in vivo doses in humans or animals 
4. Drugs reported to be BBB-impermeable in published literature 
For the drugs that remained after the above filtering process, the primary known mode of action 
was identified through literature review. 
 
Do dissimilar drugs modulate the same biological pathways? 
The drugs identified above appeared to have little in common with each other: they were 
pharmacologically diverse with different molecular targets. Dissimilar drugs with disparate 
modes of action would appear unlikely to induce the same antiepileptic phenotype. We 
hypothesized that the identified drugs, in spite of their different modes of action, modulate the 
same biological pathways, enabling them to induce the same therapeutic effect. To test this 
hypothesis, Drug-Set Enrichment Analysis (DSEA), which is based upon concepts similar to 
those first introduced by Hegde and colleagues (48), was utilized. DSEA (49) is designed to 
search the transcriptional responses of different drugs for shared pathways whose genes are 
upregulated (or downregulated) by the drugs in the set. If drugs in a drug-set tend to modulate 
the same pathway more than the other drugs in the database, this pathway will be detected by 
DSEA. A set of drugs of interest is tested against a database of pathways. Each pathway in the 
database is stored as a ranked list of drugs, sorted from the one most up-regulating the pathway 
to the one most down-regulating it. Given a query-set of drugs, DSEA checks for each pathway 
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whether the drugs tend to be significantly ranked at the top (or the bottom) of the list, by 
applying a Kolmogorov-Smirnov (KS) test. A KS p-value can thus be computed for each 
pathway. P-values assess how much the ranks of the chosen drugs are consistently small (up-
regulation) or large (down-regulation) for each pathway. The final output of DSEA is a list of 
pathways ranked by the p-value. 
 
The current DSEA database is based upon the cMap 2.0 dataset containing transcriptional 
profiles for 1309 drugs. Of the compounds identified through our drug repurposing pipeline, five 
(camptothecin, mepacrine, quinidine, resveratrol and scriptaid) are found in the cMap 2.0 and, 
hence, DSEA database. This subset is an unselected sample of five different drugs with widely 
varying modes of action and, hence, a suitable collection with which to test our hypothesis that 
GBR-identified drugs, though seemingly dissimilar, modulate the same pathways. 
 
The five drugs were analysed using the DSEA webserver (http://dsea.tigem.it). The number of 
significant Reactome pathways (p<0.05) shared by these five drugs was counted. In order to 
determine if the number of pathways shared by the GBR-identified drugs is statistically 
significant, 1000 randomly-selected five-compound drug-sets were also analysed through the 
webserver, and the number of shared pathways was counted for each random set. 
 
Are repurposable drugs better than conventional AEDs at reversing the pathway dysregulation 
underlying epilepsy? 
We wished to determine if repurposable drugs were more effective than conventional AEDs at 
correcting the pathway dysregulation underlying TLE. The DSEA dataset was again used for this 
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analysis. As stated above, each pathway in the DSEA database is stored as a ranked list of drugs, 
sorted from the one most up-regulating the pathway to the one most down-regulating it. Hence, 
for any pathway up- or down-regulated in disease, the DSEA dataset can by utilized for 
identifying the compound most effective at reversing the dysregulation.  
 
As mentioned above, of the compounds identified through our drug repurposing pipeline, five 
(camptothecin, mepacrine, quinidine, resveratrol and scriptaid) are found in the DSEA database. 
The following eight conventional AEDs are in the DSEA database: acetazolamide, 
carbamazepine, ethosuximide, gabapentin, primidone, topiramate, valproic acid and vigabatrin. 
This set of drugs is an unselected sample of different compounds with widely varying modes of 
action and, hence, a suitable collection with which to test our hypothesis that repurposable drugs 
are better than conventional AEDs at reversing the pathway dysregulation underlying TLE. 
 
The Reactome pathways most significantly dysregulated in TLE were identified by performing 
Gene-Set Enrichment Analysis (http://www.broadinstitute.org/gsea/) separately on the up- and 
down-regulated genes constituting the transcriptomic signature of TLE identified above. The 
hundred most up-regulated and the hundred most down-regulated pathways were noted; the 
degree of enrichment was statistically significant (FDR<0.05) for all of these 200 pathways 
 
The following strategy was adopted:  
1. in turn, compare each repurposable drug with the set of conventional AEDs,  
2. for each dysregulated pathway, determine if the repurposable drug is better than 
conventional AEDs at rectifying the dysregulation, 
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3. determine if the repurposable drug outperforms conventional AEDs for more pathways 
than expected by chance alone. 
The exact binomial test (R 3.2.4) was used to determine if the fraction of dysregulated pathways 
for which the repurposable drug surpasses conventional AEDs is statistically significant. 
 
Is the set of identified compounds enriched with AEDs? 
We hypothesized that the set of compounds identified through GBR is enriched with drugs of 
known antiepileptic efficacy. In order to test this hypothesis, the following strategy was devised: 
1. Each of the compounds in the LINCS database was annotated as either having published 
evidence of antiepileptic efficacy or lacking published evidence of antiepileptic efficacy. 
2. Based on the above, we determined the number of compounds with evidence of 
antiepileptic efficacy amongst our set of repurposable drugs. 
3. To determine if compounds with antiepileptic efficacy are overrepresented in our set of 
repurposable drugs, the LINCS compounds were divided into random sets of the same 
size as the repurposed set, and the number of drugs with antiepileptic efficacy was 
determined for each random set. 
For added robustness, we also used the hypergeometric distribution (R 3.3.2) to determine the 
statistical significance of the enrichment of compounds with antiepileptic efficacy within our set 
of repurposable drugs. 
 
For the above analysis, we included all 123 drugs identified by the LINCS computational 
algorithm, rather than the 36 that remained after application of exclusion criteria, as the latter 
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manual filtering steps might inadvertently advantage our chosen drug set. Annotation of the 
LINCS compounds according to evidence of antiepileptic efficacy was not limited to licensed 
AEDs, but included all drugs with evidence of efficacy in recognised animal models of epilepsy 
and seizures. In order to ensure that this process is objective, an unsupervised computational 
approach was adopted for parsing information from Medline abstracts about antiepileptic 
efficacy of the LINCS compounds. As there are ~20,000 drugs in the LINCS database, a solely 
manual literature search would, in any case, be impracticable. A clear predefined search strategy 
and vocabulary of search terms was used for this data collection. Abstracts were downloaded 
from Medline and then automatically parsed (auto-parsed) using Unix command line text 
manipulation tools. Methodological details are provided in the supplementary material, including 
search terms and synonyms used for the Medline search and auto-parsing, and the Unix 
commands utilised. In order to maximise the relevance of  the auto-parsed data, we sought 
sentence-level concurrence of search terms, which increases specificity and precision of data 
retrieval (50). A Medline abstract sentence was extracted if the following search terms concurred 
within it: the name of a compound from the LINCS database, suppression (or a synonym 
thereof), seizures (or a synonym thereof), and the name of a recognised rodent model of epilepsy 
or seizures. 
 
The results of the auto-parsing were manually reviewed to exclude any irrelevant results. 
Exclusion was based on clear objective pre-defined criteria: drugs were excluded if the 
information parsed (1) did not clearly indicate evidence of independent clinical antiepileptic 
efficacy, or (2) indicated promotion, rather than inhibition, of seizures by the drug.  
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It is important to note that these data are not presented as a comprehensive list of all drugs with 
published evidence of antiepileptic efficacy, but rather as a tool for objectively testing the 
overrepresentation of such drugs within the repurposable drug-set. 
 
In addition to above unsupervised computational approach for parsing information from Medline 
abstracts, which was applied to all 123 drugs identified by the LINCS computational algorithm, a 
more detailed manual literature-review was performed in order to identify additional evidence of 
antiepileptic efficacy for the 36 compounds that were selected after application of exclusion 
criteria. 
 
In vivo validation 
For in vivo validation, we wished to choose a drug that: (1) was previously unstudied in animal 
models of epilepsy, and (2) had Medicines and Healthcare products Regulatory Agency (MHRA) 
or European Medicines Agency (EMA) approval and extensive data of routine safe clinical use 
in humans, as such a drug would encounter the fewest research and regulatory barriers on the 
repurposing pathway and will be more readily adopted by the clinical community. After 
excluding drugs that already have independent published evidence of antiepileptic efficacy 
(Table 1), sitagliptin (an antihyperglycaemic) was the highest ranked MHRA/EMA-approved 
drug in routine clinical use in this country. Hence, sitagliptin was chosen for in vivo validation. 
The 6 Hz psychomotor seizure mouse model (18), a mouse model of pharmacoresistant epilepsy 
(16, 19), was used for validating the efficacy of this drug. Sitagliptin was evaluated at 3 doses—
125, 250 and 500 mg/kg—chosen because they exert a therapeutic effect without producing 
toxicity in rodent models of brain diseases (34, 51-53). Levetiracetam (100 mg/kg), an AED 
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which is well characterised and effective in this model (16, 17), was included in the drug 
screening to verify adequate execution of the screening process. Physiological saline was used as 
the vehicle control substance. Hence, five groups of mice were studied: sitagliptin 125 mg/kg, 
sitagliptin 250 mg/kg, sitagliptin 500 mg/kg, levetiracetam 100 mg/kg, and saline. There were 
fifteen male NMRI mice (Janvier Labs, France), 22 - 31 g body weight range, in each group. The 
animal experiments were performed by the Porsolt Research Laboratory (France). 
 
Compounds were administered intraperitoneally (i.p.) 60 minutes before application of the 
current. Mice were administered a rectangular current (44 mA, rectangular pulse: 0.2 ms pulse 
width, 3 s duration, 6 Hz) via corneal electrodes connected to a constant current shock generator 
(Ugo Basile: type 7801). Seizure scores were recorded for each animal. Seizure scores were 
based on the occurrence and severity of forelimb clonus: absent (0), mild (1) or strong (2). 
Presence or absence of Straub tail was also recorded, but it was noted that Straub tail was 
observed in some animals in the absence of forelimb seizures and, hence, this feature was not 
used in the evaluation. Each test was performed blind. 
 
Statistical analysis 
For the bioinformatic analyses, permutation-based approaches used to determine statistical 
significance have been described in the relevant sections above. A two-sided exact binomial test 
(R 3.2.4) was used to determine if the fraction of dysregulated pathways for which the 
repurposable drug surpasses conventional AEDs is statistically significant. For the in vivo 
analysis, seizure scores across all groups were compared using the Kruskal–Wallis test; threshold 
of statistical significance was p<0.05. For post hoc analysis, seizure scores for each of the drug 
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treated groups were compared with the vehicle control group using a two-sided Mann-Whitney 
U test, with Benjamini and Hochberg false discovery rate (FDR) correction for multiple testing; 
threshold of statistical significance was FDR<0.05. All statistical calculations were performed 
using R 3.2.4. G*Power version 3.1 (54) was used to calculate the power of the two-tailed Mann-
Whitney U test (α = 0.05). 
 
Supplementary Materials 
Supplementary Methods 
Supplementary Results 
Supplementary tables: 
Table S1. Genes constituting the transcriptomic signature of epilepsy used in the current study  
Table S2. Compounds meeting the LINCS mean connectivity score inclusion threshold of -85 
Table S3. Compounds retained after applying the exclusion criteria 
Table S4. DSEA output for the set of five GBR-identified drugs 
Table S5. Number of Reactome pathways shared by 1000 randomly-selected five-drugs sets at a 
significance threshold of p<0.05 
Table S6. The percentage of dysregulated pathways corrected most effectively by each drug in 
the comparison.  
Table S7. Medline search terms used  
Table S8. Search terms and synonyms used for auto-parsing 
Table S9. 6 Hz psychomotor seizures model seizure scores 
24 
 
Supplementary data: Included drugs 
Supplementary data: Excluded drugs 
Acknowledgements 
NM was funded by a Medical Research Council Research Training Fellowship. MP is an NIHR 
Senior Investigator, and acknowledges support from the NHS Chair of Pharmacogenetics and the 
MRC Centre for Drug Safety Science.  
Conflicts of interest 
None. 
 
 
References and Notes: 
1. A. K. Ngugi, C. Bottomley, I. Kleinschmidt, J. W. Sander, C. R. Newton, Estimation of the burden of 
active and life-time epilepsy: a meta-analytic approach. Epilepsia 51, 883 (May, 2010). 
2. M. J. Brodie, Antiepileptic drug therapy the story so far. Seizure : the journal of the British Epilepsy 
Association 19, 650 (Dec, 2010). 
3. S. D. Shorvon, The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia 37 Suppl 2, 
S1 (1996). 
4. W. Loscher, C. Brandt, Prevention or modification of epileptogenesis after brain insults: experimental 
approaches and translational research. Pharmacological reviews 62, 668 (Dec, 2010). 
5. A. Pitkanen et al., Issues related to development of antiepileptogenic therapies. Epilepsia 54 Suppl 4, 35 
(Aug, 2013). 
6. G. L. Holmes, J. L. Noebels, The Epilepsy Spectrum: Targeting Future Research Challenges. Cold Spring 
Harbor perspectives in medicine 6,  (2016). 
7. F. Iorio, T. Rittman, H. Ge, M. Menden, J. Saez-Rodriguez, Transcriptional data: a new gateway to drug 
repositioning? Drug discovery today 18, 350 (Apr, 2013). 
8. A. Wagner et al., Drugs that reverse disease transcriptomic signatures are more effective in a mouse model 
of dyslipidemia. Molecular systems biology 11, 791 (Jan, 2015). 
9. M. Sirota et al., Discovery and preclinical validation of drug indications using compendia of public gene 
expression data. Science translational medicine 3, 96ra77 (Aug 17, 2011). 
10. J. T. Dudley et al., Computational repositioning of the anticonvulsant topiramate for inflammatory bowel 
disease. Science translational medicine 3, 96ra76 (Aug 17, 2011). 
11. N. S. Jahchan et al., A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small 
cell lung cancer and other neuroendocrine tumors. Cancer discovery 3, 1364 (Dec, 2013). 
12. D. Speed et al., Describing the genetic architecture of epilepsy through heritability analysis. Brain : a 
journal of neurology 137, 2680 (Oct, 2014). 
25 
 
13. N. Mirza et al., Identifying the biological pathways underlying human focal epilepsy: from complexity to 
coherence to centrality. Human molecular genetics 24, 4306 (Aug 1, 2015). 
14. N. Mirza, O. Vasieva, A. G. Marson, M. Pirmohamed, Exploring the genomic basis of pharmacoresistance 
in epilepsy: an integrative analysis of large-scale gene expression profiling studies on brain tissue from 
epilepsy surgery. Human molecular genetics 20, 4381 (Nov 15, 2011). 
15. K. F. Hansen, K. Sakamoto, C. Pelz, S. Impey, K. Obrietan, Profiling status epilepticus-induced changes in 
hippocampal RNA expression using high-throughput RNA sequencing. Scientific reports 4, 6930 (2014). 
16. M. E. Barton, B. D. Klein, H. H. Wolf, H. S. White, Pharmacological characterization of the 6 Hz 
psychomotor seizure model of partial epilepsy. Epilepsy research 47, 217 (Dec, 2001). 
17. N. M. Rowley, H. S. White, Comparative anticonvulsant efficacy in the corneal kindled mouse model of 
partial epilepsy: Correlation with other seizure and epilepsy models. Epilepsy research 92, 163 (Dec, 
2010). 
18. W. C. Brown, D. O. Schiffman, E. A. Swinyard, L. S. Goodman, Comparative assay of an antiepileptic 
drugs by psychomotor seizure test and minimal electroshock threshold test. The Journal of pharmacology 
and experimental therapeutics 107, 273 (Mar, 1953). 
19. W. Loscher, Critical review of current animal models of seizures and epilepsy used in the discovery and 
development of new antiepileptic drugs. Seizure : the journal of the British Epilepsy Association 20, 359 
(Jun, 2011). 
20. M. Obeid, E. C. Rosenberg, P. M. Klein, F. E. Jensen, Lestaurtinib (CEP-701) attenuates "second hit" 
kainic acid-induced seizures following early life hypoxic seizures. Epilepsy research 108, 806 (May, 2014). 
21. A. Siniscalchi, S. Mintzer, Statins for poststroke seizures: the first antiepileptogenic agent? Neurology 85, 
661 (Aug 25, 2015). 
22. N. Sehar, N. B. Agarwal, D. Vohora, S. Raisuddin, Atorvastatin prevents development of kindling by 
modulating hippocampal levels of dopamine, glutamate, and GABA in mice. Epilepsy & behavior : E&B 
42, 48 (Jan, 2015). 
23. R. Citraro et al., Protective effects of some statins on epileptogenesis and depressive-like behavior in 
WAG/Rij rats, a genetic animal model of absence epilepsy. Epilepsia 55, 1284 (Aug, 2014). 
24. J. Guo et al., Statin treatment reduces the risk of poststroke seizures. Neurology 85, 701 (Aug 25, 2015). 
25. L. Kandratavicius, J. E. Hallak, C. G. Carlotti, Jr., J. A. Assirati, Jr., J. P. Leite, Hippocampal expression of 
heat shock proteins in mesial temporal lobe epilepsy with psychiatric comorbidities and their relation to 
seizure outcome. Epilepsia 55, 1834 (Nov, 2014). 
26. C. E. Stafstrom, Epilepsy comorbidities: how can animal models help? Advances in experimental medicine 
and biology 813, 273 (2014). 
27. M. S. Hester, S. C. Danzer, Hippocampal granule cell pathology in epilepsy - a possible structural basis for 
comorbidities of epilepsy? Epilepsy & behavior : E&B 38, 105 (Sep, 2014). 
28. A. Gaitatzis, S. M. Sisodiya, J. W. Sander, The somatic comorbidity of epilepsy: a weighty but often 
unrecognized burden. Epilepsia 53, 1282 (Aug, 2012). 
29. A. Mazarati, R. Sankar, Common Mechanisms Underlying Epileptogenesis and the Comorbidities of 
Epilepsy. Cold Spring Harbor perspectives in medicine 6,  (2016). 
30. G. Uzum, K. Akgun-Dar, U. Aksu, The effects of atorvastatin on memory deficit and seizure susceptibility 
in pentylentetrazole-kindled rats. Epilepsy & behavior : E&B 19, 284 (Nov, 2010). 
31. K. M. Choudhary, A. Mishra, V. V. Poroikov, R. K. Goel, Ameliorative effect of Curcumin on seizure 
severity, depression like behavior, learning and memory deficit in post-pentylenetetrazole-kindled mice. 
European journal of pharmacology 704, 33 (Mar 15, 2013). 
32. M. Ahmad, G. M. Abu-Taweel, A. E. Aboshaiqah, J. S. Ajarem, The effects of quinacrine, proglumide, and 
pentoxifylline on seizure activity, cognitive deficit, and oxidative stress in rat lithium-pilocarpine model of 
status epilepticus. Oxidative medicine and cellular longevity 2014, 630509 (2014). 
33. M. Smith, K. S. Wilcox, H. S. White, Discovery of antiepileptic drugs. Neurotherapeutics : the journal of 
the American Society for Experimental NeuroTherapeutics 4, 12 (Jan, 2007). 
34. S. Lim et al., Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation 
after balloon injury in rats. PloS one 7, e35007 (2012). 
35. F. Briand, Q. Thieblemont, R. Burcelin, T. Sulpice, Sitagliptin promotes macrophage-to-faeces reverse 
cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-
apoB100 transgenic mice. Diabetes, obesity & metabolism 14, 662 (Jul, 2012). 
36. M. A. Darracq, J. M. Toy, T. Chen, C. Mo, F. L. Cantrell, A retrospective review of isolated gliptin-
exposure cases reported to a state poison control system. Clin Toxicol (Phila) 52, 226 (Mar, 2014). 
26 
 
37. P. Aschner et al., Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic 
control in patients with type 2 diabetes. Diabetes care 29, 2632 (Dec, 2006). 
38. Z. Wang et al., Transcriptome analysis of the hippocampus in novel rat model of febrile seizures. PloS one 
9, e95237 (2014). 
39. M. R. Johnson et al., Systems genetics identifies Sestrin 3 as a regulator of a proconvulsant gene network 
in human epileptic hippocampus. Nature communications 6, 6031 (2015). 
40. P. Roncon et al., MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-
induced epilepsy--comparison with human epileptic samples. Scientific reports 5, 14143 (2015). 
41. W. Loscher, H. Klitgaard, R. E. Twyman, D. Schmidt, New avenues for anti-epileptic drug discovery and 
development. Nature reviews. Drug discovery 12, 757 (Oct, 2013). 
42. J. T. Eppig, J. A. Blake, C. J. Bult, J. A. Kadin, J. E. Richardson, The Mouse Genome Database (MGD): 
facilitating mouse as a model for human biology and disease. Nucleic acids research 43, D726 (Jan, 2015). 
43. G. Liu et al., NetAffx: Affymetrix probesets and annotations. Nucleic acids research 31, 82 (Jan 1, 2003). 
44. J. Lamb et al., The Connectivity Map: using gene-expression signatures to connect small molecules, genes, 
and disease. Science 313, 1929 (Sep 29, 2006). 
45. Y. A. Lussier, J. L. Chen, The emergence of genome-based drug repositioning. Science translational 
medicine 3, 96ps35 (Aug 17, 2011). 
46. J. C. Siavelis, M. M. Bourdakou, E. I. Athanasiadis, G. M. Spyrou, K. S. Nikita, Bioinformatics methods in 
drug repurposing for Alzheimer's disease. Briefings in bioinformatics 17, 322 (Mar, 2016). 
47. K. Traynor, NIOSH revamps hazardous drugs update. American journal of health-system pharmacy : AJHP 
: official journal of the American Society of Health-System Pharmacists 71, 2099 (Dec 15, 2014). 
48. R. N. Hegde et al., Unravelling druggable signalling networks that control F508del-CFTR proteostasis. 
Elife 4,  (Dec 23, 2015). 
49. F. Napolitano, F. Sirci, D. Carrella, D. di Bernardo, Drug-set enrichment analysis: a novel tool to 
investigate drug mode of action. Bioinformatics 32, 235 (Jan 15, 2016). 
50. M. S. Siadaty, J. Shu, W. A. Knaus, Relemed: sentence-level search engine with relevance score for the 
MEDLINE database of biomedical articles. BMC medical informatics and decision making 7, 1 (2007). 
51. A. E. El-Sahar, M. M. Safar, H. F. Zaki, A. S. Attia, A. A. Ain-Shoka, Sitagliptin attenuates transient 
cerebral ischemia/reperfusion injury in diabetic rats: implication of the oxidative-inflammatory-apoptotic 
pathway. Life sciences 126, 81 (Apr 1, 2015). 
52. H. D. Theiss et al., Antidiabetic gliptins in combination with G-CSF enhances myocardial function and 
survival after acute myocardial infarction. International journal of cardiology 168, 3359 (Oct 9, 2013). 
53. C. Brenner et al., Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial 
injury via enhanced recruitment of circulating progenitor cells. International journal of cardiology 177, 266 
(Nov 15, 2014). 
54. F. Faul, E. Erdfelder, A. G. Lang, A. Buchner, G*Power 3: a flexible statistical power analysis program for 
the social, behavioral, and biomedical sciences. Behavior research methods 39, 175 (May, 2007). 
55. L. A. Etherington et al., Astrocytic adenosine kinase regulates basal synaptic adenosine levels and seizure 
activity but not activity-dependent adenosine release in the hippocampus. Neuropharmacology 56, 429 
(Feb, 2009). 
56. G. Zhang, P. H. Franklin, T. F. Murray, Manipulation of endogenous adenosine in the rat prepiriform 
cortex modulates seizure susceptibility. The Journal of pharmacology and experimental therapeutics 264, 
1415 (Mar, 1993). 
57. N. Gouder, L. Scheurer, J. M. Fritschy, D. Boison, Overexpression of adenosine kinase in epileptic 
hippocampus contributes to epileptogenesis. The Journal of neuroscience : the official journal of the 
Society for Neuroscience 24, 692 (Jan 21, 2004). 
58. B. G. Ugarkar et al., Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity 
of 5-iodotubercidin analogues. Journal of medicinal chemistry 43, 2883 (Jul 27, 2000). 
59. J. B. Wiesner et al., Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy. The Journal 
of pharmacology and experimental therapeutics 289, 1669 (Jun, 1999). 
60. R. M. Kaminski, H. Marini, P. I. Ortinski, S. Vicini, M. A. Rogawski, The pheromone androstenol (5 
alpha-androst-16-en-3 alpha-ol) is a neurosteroid positive modulator of GABAA receptors. The Journal of 
pharmacology and experimental therapeutics 317, 694 (May, 2006). 
61. E. Russo et al., Pharmacodynamic potentiation of antiepileptic drugs' effects by some HMG-CoA reductase 
inhibitors against audiogenic seizures in DBA/2 mice. Pharmacological research : the official journal of 
the Italian Pharmacological Society 70, 1 (Apr, 2013). 
27 
 
62. H. Shafaroodi et al., The involvement of nitric oxide in the anti-seizure effect of acute atorvastatin 
treatment in mice. Neurological research 34, 847 (Nov, 2012). 
63. J. K. Lee, J. S. Won, A. K. Singh, I. Singh, Statin inhibits kainic acid-induced seizure and associated 
inflammation and hippocampal cell death. Neuroscience letters 440, 260 (Aug 8, 2008). 
64. K. Moazzami, S. Emamzadeh-Fard, M. Shabani, Anticonvulsive effect of atorvastatin on 
pentylenetetrazole-induced seizures in mice: the role of nitric oxide pathway. Fundamental & clinical 
pharmacology 27, 387 (Aug, 2013). 
65. L. Moezi et al., Chronic administration of atorvastatin induced anti-convulsant effects in mice: the role of 
nitric oxide. Epilepsy & behavior : E&B 23, 399 (Apr, 2012). 
66. V. R. Funck et al., Differential effects of atorvastatin treatment and withdrawal on pentylenetetrazol-
induced seizures. Epilepsia 52, 2094 (Nov, 2011). 
67. T. C. Piermartiri et al., Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced 
seizures in mice by increasing Akt phosphorylation and glutamate uptake. Neurotoxicity research 16, 106 
(Aug, 2009). 
68. J. Song, L. Parker, L. Hormozi, M. A. Tanouye, DNA topoisomerase I inhibitors ameliorate seizure-like 
behaviors and paralysis in a Drosophila model of epilepsy. Neuroscience 156, 722 (Oct 15, 2008). 
69. A. M. Orellana-Paucar et al., Anticonvulsant activity of bisabolene sesquiterpenoids of Curcuma longa in 
zebrafish and mouse seizure models. Epilepsy & behavior : E&B 24, 14 (May, 2012). 
70. P. Du et al., Curcumin inhibits amygdaloid kindled seizures in rats. Chinese medical journal 122, 1435 
(Jun 20, 2009). 
71. N. B. Agarwal et al., Liposomal formulation of curcumin attenuates seizures in different experimental 
models of epilepsy in mice. Fundamental & clinical pharmacology 27, 169 (Apr, 2013). 
72. N. Bharal, K. Sahaya, S. Jain, P. K. Mediratta, K. K. Sharma, Curcumin has anticonvulsant activity on 
increasing current electroshock seizures in mice. Phytotherapy research : PTR 22, 1660 (Dec, 2008). 
73. A. Jyoti, P. Sethi, D. Sharma, Curcumin protects against electrobehavioral progression of seizures in the 
iron-induced experimental model of epileptogenesis. Epilepsy & behavior : E&B 14, 300 (Feb, 2009). 
74. Y. K. Gupta, S. Briyal, M. Sharma, Protective effect of curcumin against kainic acid induced seizures and 
oxidative stress in rats. Indian journal of physiology and pharmacology 53, 39 (Jan-Mar, 2009). 
75. E. Tamaddonfard, A. Erfanparast, N. Hamzeh-Gooshchi, S. Yousofizadeh, Effect of curcumin, the active 
constituent of turmeric, on penicillin-induced epileptiform activity in rats. Avicenna journal of 
phytomedicine 2, 196 (Fall, 2012). 
76. L. Saha, A. Chakrabarti, S. Kumari, A. Bhatia, D. Banerjee, Antiapoptotic and neuroprotective role of 
Curcumin in Pentylenetetrazole (PTZ) induced kindling model in rat. Indian journal of experimental 
biology 54, 133 (Feb, 2016). 
77. W. Zhu, J. Su, J. Liu, C. Jiang, The involvement of neuronal nitric oxide synthase in the anti-epileptic 
action of curcumin on pentylenetetrazol-kindled rats. Bio-medical materials and engineering 26 Suppl 1, 
S841 (2015). 
78. K. K. Akula, S. K. Kulkarni, Effect of curcumin against pentylenetetrazol-induced seizure threshold in 
mice: possible involvement of adenosine A1 receptors. Phytotherapy research : PTR 28, 714 (May, 2014). 
79. J. Mehla, K. H. Reeta, P. Gupta, Y. K. Gupta, Protective effect of curcumin against seizures and cognitive 
impairment in a pentylenetetrazole-kindled epileptic rat model. Life sciences 87, 596 (Nov 20, 2010). 
80. N. A. Noor, H. S. Aboul Ezz, A. R. Faraag, Y. A. Khadrawy, Evaluation of the antiepileptic effect of 
curcumin and Nigella sativa oil in the pilocarpine model of epilepsy in comparison with valproate. Epilepsy 
& behavior : E&B 24, 199 (Jun, 2012). 
81. H. S. Ezz, Y. A. Khadrawy, N. A. Noor, The neuroprotective effect of curcumin and Nigella sativa oil 
against oxidative stress in the pilocarpine model of epilepsy: a comparison with valproate. Neurochemical 
research 36, 2195 (Nov, 2011). 
82. M. Ahmad, Protective effects of curcumin against lithium-pilocarpine induced status epilepticus, cognitive 
dysfunction and oxidative stress in young rats. Saudi journal of biological sciences 20, 155 (Apr, 2013). 
83. N. B. Agarwal, S. Jain, N. K. Agarwal, P. K. Mediratta, K. K. Sharma, Modulation of pentylenetetrazole-
induced kindling and oxidative stress by curcumin in mice. Phytomedicine : international journal of 
phytotherapy and phytopharmacology 18, 756 (Jun 15, 2011). 
84. Z. Jiang et al., Protection against cognitive impairment and modification of epileptogenesis with curcumin 
in a post-status epilepticus model of temporal lobe epilepsy. Neuroscience 310, 362 (Dec 3, 2015). 
28 
 
85. J. Auta et al., Participation of mitochondrial diazepam binding inhibitor receptors in the anticonflict, 
antineophobic and anticonvulsant action of 2-aryl-3-indoleacetamide and imidazopyridine derivatives. The 
Journal of pharmacology and experimental therapeutics 265, 649 (May, 1993). 
86. E. Romeo et al., 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the 
mitochondrial DBI receptor (MDR). The Journal of pharmacology and experimental therapeutics 262, 971 
(Sep, 1992). 
87. M. Tsuda, T. Suzuki, M. Misawa, Subsensitivity to mitochondrial diazepam binding inhibitor receptor 
agonist FGIN-1-27-induced antiseizure effect in diazepam-withdrawn mice. Life sciences 62, PL213 
(1998). 
88. M. Steriade, E. Stoica, On the anticonvulsive effect of quinidine. I. Experimental investigation of 
somatomotor, vegetative and bioelectrical aspects of convulsive seizures elicited by electroshocks. 
Epilepsia 1, 264 (Apr, 1960). 
89. M. Steriade, E. Stoica, On the anticonvulsive effect of quinidine. II. Experimental investigations of focal 
electrical after-discharge and penicillin epilepsy. Epilepsia 1, 275 (Apr, 1960). 
90. Y. K. Gupta, G. Chaudhary, K. Sinha, A. K. Srivastava, Protective effect of resveratrol against intracortical 
FeCl3-induced model of posttraumatic seizures in rats. Methods and findings in experimental and clinical 
pharmacology 23, 241 (Jun, 2001). 
91. U. Hoda, N. B. Agarwal, D. Vohora, S. Parvez, S. Raisuddin, Resveratrol suppressed seizures by 
attenuating IL-1beta, IL1-Ra, IL-6, and TNF-alpha in the hippocampus and cortex of kindled mice. 
Nutritional neuroscience, 1 (Jun 2, 2016). 
92. Y. K. Gupta, S. Briyal, G. Chaudhary, Protective effect of trans-resveratrol against kainic acid-induced 
seizures and oxidative stress in rats. Pharmacology, biochemistry, and behavior 71, 245 (Jan-Feb, 2002). 
93. Z. Wu et al., Protective effect of resveratrol against kainate-induced temporal lobe epilepsy in rats. 
Neurochemical research 34, 1393 (Aug, 2009). 
94. Y. K. Gupta, G. Chaudhary, A. K. Srivastava, Protective effect of resveratrol against pentylenetetrazole-
induced seizures and its modulation by an adenosinergic system. Pharmacology 65, 170 (Jul, 2002). 
95. L. Saha, A. Chakrabarti, Understanding the anti-kindling role and its mechanism of Resveratrol in 
Pentylenetetrazole induced-kindling in a rat model. Pharmacology, biochemistry, and behavior 120, 57 
(May, 2014). 
 
 
Legends to figures:  
Fig. 1. Percentage of dysregulated pathways corrected most effectively by each drug in the 
comparison. Asterisk indicates that the fraction of dysregulated pathways for which the 
repurposable drug surpassed conventional AEDs was statistically significant (binomial 
test FDR<0.05) 
Tables: 
Table 1. Drugs, from amongst the 36 GBR-identified compounds, that have evidence of 
antiepileptic or antiepileptogenic efficacy in animal models or humans. Please note that in the 
study by Guo and colleagues (24) most patients received atorvastatin;  there were not enough 
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data to conduct appropriate subgroup analyses because too few patients were given simvastatin 
or rosuvastatin. 
Drug Mechanism of 
action 
Summarised evidence of antiepileptic and 
antiepileptogenic efficacy 
5-iodotubercidin Adenosine 
kinase inhibitor 
 
 
Suppression of epileptiform activity evoked by brief, 
high-frequency stimulation in rat hippocampal slices 
(55). Antiepileptic effect in rodent bicuculline (56), 
kainic acid (57), maximal electric shock (58, 59) 
models. 
Androstenol Neurosteroid, 
GABAA receptor 
modulator 
Antiepileptic effect in the rodent 6 Hz electroshock and 
pentylenetetrazol (60) models 
Atorvastatin HMG-CoA 
reductase 
inhibitor 
Antiepileptic effect in the rodent DBA/2 audiogenic 
seizures (61), increasing current electroshock (22, 62), 
kainic acid (63), pentylenetetrazole (30, 62, 64-66), and 
quinolinic acid (67) models. Antiepileptogenic effect in 
the rodent pentylenetetrazole (22) and WAG/Rij (23) 
models. Association with reduced risk of poststroke 
epilepsy in patients (24). 
Camptothecin Inhibitor of DNA 
topoisomerase I 
Antiepileptic effect in a Drosophila model of epilepsy 
(68) 
Curcumin Antioxidant Antiepileptic effect in the zebrafish model (69), and in 
rodent amygdaloid kindling (70), increasing current 
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electroshock (71, 72), iron-induced epileptogenesis 
(73), kainic acid (74), penicillin-induced epileptiform 
activity (75), pentylenetetrazole (31, 71, 76-79), and 
pilocarpine (80, 81) models. Anticonvulsant in 
pilocarpine- (82) and pentylenetetrazol-induced status 
epilepticus (71). Protects against pentylenetetrazole-
induced kindling (83), and exerts a favourable disease-
modifying effect in the kainic acid model (84). 
FGIN-1-27 Mitochondrial 
benzodiazepine 
receptor agonist 
Antiepileptic effect in the rodent isoniazid (85, 86), 
metrazol (85) and pentylenetetrazole (87) model. 
Lestaurtinib Tyrosine kinase 
inhibitor 
Antiepileptogenic effect in rats: administration of 
lestaurtinib within 12 hours of the first neonatal seizure 
attenuates increased susceptibility to seizures in later 
life (20). 
Mepacrine Multiple actions, 
including 
inhibition of 
PLA2 
Antiepileptic effect in the rodent lithium-pilocarpine 
(32) model. 
Quinidine Sodium channel 
blocker 
Antiepileptic effect in electroshock (88) and penicillin-
induced (89) seizures in cats. 
Resveratrol Produced 
naturally by 
Antiepileptic effect in the rodent FeCl3 (90), increasing 
current electroshock (91), kainic acid (92, 93), and 
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several plants; 
principal mode 
of action 
unknown 
pentylenetetrazole (94) models. Antiepileptogenic 
effect in the rodent pentylenetetrazole model (91, 95). 
Sitagliptin Dipeptidyl 
peptidase-4 
inhibitor 
Antiepileptic effect: sitagliptin produces a dose-
dependent reduction in seizures in a mouse-model of 
drug-resistant epilepsy (current study) 
 
 
 
 
 
 
